- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
C. Nucci et al. (Eds.)
Progress in Brain Research, Vol. 173
ISSN 0079-6123
Copyright r 2008 Elsevier B.V. All rights reserved
CHAPTER 21
Rat models for glaucoma research
John C. Morrison , Elaine Johnson and William O. Cepurna
Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA
Abstract: Rats are becoming an increasingly popular model system for understanding mechanisms of optic nerve injury in primary open-angle glaucoma (POAG). Although the anatomy of the rat optic nerve head (ONH) is different from the human, the ultrastructural relationships between astrocytes and axons are quite similar, making it likely that cellular processes of axonal damage in these models will be relevant to human glaucoma. All of these models rely on elevating intraocular pressure (IOP), a major risk factor for glaucoma. Methods that produce increased resistance to aqueous humor outflow at the anterior chamber angle, specifically hypertonic saline injection of aqueous outflow pathways and laser treatment of the limbal tissues, appear to produce a specific regional pattern of injury that may have a particular relevance to understanding regional injury in human glaucoma. Because increased pressure fluctuations are a characteristic of such models and the rodent ONH appears to have high susceptibility to elevated IOP, special instrumentation and measurement techniques are required to document pressure exposure in these eyes and understand the pressure levels that the eyes and the optic nerve are exposed to. With these techniques, it is possible to obtain an excellent correlation between pressure and the extent of nerve damage. Continued use of these models will lead to a better understanding of cellular mechanisms of pressure-induced optic nerve damage and POAG.
Keywords: glaucoma; intraocular pressure; optic nerve damage; astrocyte; axon; optic nerve head; animal models
Rat models for glaucoma research
Primary open-angle glaucoma (POAG) is the most common form of glaucoma in the United States and Europe. This is a slowly progressive form of optic nerve damage and blindness that begins with loss of peripheral vision and is followed by gradual shrinkage of remaining central vision and, ultimately, disappearance of even central, sharp
Corresponding author. Tel.: +1 503 494 3038; Fax: +1 503 494 3075; E-mail: morrisoj@ohsu.edu
vision. Unfortunately, blindness is irreversible, as optic nerve fibers do not regenerate.
Clinically, glaucoma is recognized by characteristic ‘‘cupping’’ of the optic nerve head (ONH). Cupping results from loss of retinal ganglion cell (RGC) axons, combined with collapse and posterior bowing of their supporting connective tissue sheets, or lamina cribrosa. In many patients, these physical changes are most pronounced in the superior and inferior poles of the ONH, leading to vertical enlargement of the cup and eventual undermining of the neural rim beneath the edge of the sclera in these areas.
DOI: 10.1016/S0079-6123(08)01121-7 |
285 |
286
This regional glaucoma injury produces a specific pattern of visual field loss (Quigley and Green, 1979; Quigley et al., 1981, 1988, 1989; Kerrigan-Baumrind et al., 2000). The most characteristic field defect in glaucoma (the arcuate defect) arches either above or below fixation, following the path of the nerve fiber bundles that pass through the superior and inferior poles of the optic nerve (Sommer et al., 1991; Tuulonen and Airaksinen, 1991). In glaucomatous optic nerve cross sections, this results in an ‘‘hour-glass’’ configuration of damage, with the greatest atrophy in the superior and inferior regions (Quigley and Green, 1979).
The best explanation for this injury pattern appears to lie in the structure of the ONH. In humans and other species with relatively large eyes, structural support to the optic nerve bundles is provided by the lamina cribrosa, which consists multiple ‘‘plates’’ of connective tissue that span the scleral opening, with pores that allow the optic nerve fiber bundles to exit the eye (Hernandez, 1992; Morrison et al., 1994). In humans, the pores of the superior and inferior laminas appear larger than elsewhere, and their connective tissue beams are thinner and more sparse (Quigley et al., 1981; Radius, 1981). This suggests that the thinner lamina cribrosa in these regions provides less adequate support for nerve fibers, increasing their risk for glaucomatous damage. This also strongly suggests that the ONH is the likely site of early injury in glaucoma, along with observations of axonal transport obstruction within the lamina in human glaucoma and animal models (Quigley et al., 1979, 1981; Pease et al., 2000; Martin et al., 2003).
Vision loss in POAG is generally slow and progressive and may take decades to develop. Clinically, it has been observed that patients with greater nerve damage and field loss can suffer progressive visual loss at levels of intraocular pressure (IOP) that would be tolerated by the eyes with less damage (Grant and Burke, 1982). This suggests that there is something unique about the glaucomatous eye that renders the remaining optic nerve fibers more susceptible to IOP.
This progressive susceptibility most likely results from gradual changes occurring in the ONH,
within RGCs, or both. Understanding these changes will help explain why many patients continue to progress despite apparently successful pressure lowering and why pressure in others is never remarkably higher than the normal range. It may also lead to the development of specific treatments designed to reverse or stabilize these conditions and preserve the remaining nerve fibers.
Because we currently lack noninvasive methods for assaying cellular function in humans, it is not yet possible to study these possibilities directly in human glaucoma. Therefore, relevant animal models will remain essential in helping us understand the mechanisms of glaucomatous optic nerve damage.
Use of animal models for POAG
Most animal models of glaucoma employ experimental elevation of IOP. Although IOP is only one of several known glaucoma risk factors, large clinical trials have confirmed that aggressive IOP lowering is beneficial in a spectrum of open-angle glaucomas, including normal-tension glaucoma, ocular hypertension, and early and late glaucoma (Drance, 1999; Kass et al., 2002; Leske et al., 2003; Nouri-Mahdavi et al., 2004b). From this, it is reasonable to expect that models based on elevated IOP will be highly relevant to optic nerve damage in open-angle glaucoma.
Experimental models of pressure-induced optic nerve damage possess certain advantages over spontaneous models. First, unilateral pressure elevation leaves the fellow eye available as a control against the effects of inter-animal variability. Second, the more predictable onset of the pressure elevation makes it possible to determine sequential events of optic nerve and retina damage.
Anatomically, nonhuman primates should be the most relevant experimental glaucoma model for studying human diseases. However, these animals are expensive, making them impractical for cell biology studies and drug trials requiring a large number of animals. Without special training and experience, it can be difficult to monitor IOP frequently enough to develop a solid understanding of the pressure insult to which the eye is exposed.
For these reasons, a less-expensive, more manageable model of pressure-induced optic nerve damage is needed. We feel this need can be supplied by laboratory rats. A large body of knowledge on the cell biology of neuropathology based on rats already exists, thus providing an array of tools for studying pressure-induced optic nerve damage when produced in these animals.
This chapter will discuss the current status of rat models that can be used to study optic nerve damage in POAG. This will include methods for measuring IOP in rats, assessing damage, and a comparison of the major experimental methods used to produce elevated IOP. We will conclude with a summary of the additional advances needed to optimize the ability of these models to help us improve care of glaucoma patients.
Suitability of the rat for models of optic nerve damage in POAG
It should be noted that the rat ONH lacks a welldeveloped, collagenous lamina cribrosa (Morrison et al., 1995a). While this differs from the primate, it does not diminish the utility of the rat for understanding cellular mechanisms of axonal injury from elevated IOP and in glaucoma (Fig. 1).
Sparse connective tissue associated with blood vessels has been described in the rat ONH, lined with astrocytes and composed of extracellular matrix materials very similar to that of the primate lamina cribrosa (Morrison et al., 1995a). We have also found that the cellular response to elevated IOP in rats is very similar to that in human and nonhuman primate glaucomas (Hernandez et al., 1990, 2000; Morrison et al., 1990; Johnson et al., 1996). This includes disorganization of the normal columnar structure of astrocytes and aberrant deposition of collagen and laminin within spaces normally occupied by axon bundles.
The most useful feature that the rat eye offers for POAG research lies in the close association between astrocytes and axons within the ONH. Ultrastructurally, rat ONH astrocyte processes lie within axonal bundles, providing intimate contact with all axons, a situation that also exists in the primate (Morrison et al., 2005) (Fig. 2). This close
287
Fig. 1. Longitudinal section of the rat ONH, demonstrating close apposition of the ONH (*) with the superior sclera (S), while the inferior sclera is separated from the ONH by central artery (A) and vein (V). Arrowheads indicate the beginning of the myelinated optic nerve, posterior to the sclera ( 400).
Fig. 2. TEM of the rat ONH cross section showing extension of astrocyte (As) processes into axon bundles. Note close contact between processes and nearly all axons, which are cut in cross section ( 30,000).
association between axons and astrocytes, which rest on the connective tissue lamina and peripapillary sclera of the ONH, provides a potential link by which IOP-generated forces in the load-bearing tissues of the ONH can get translated into axonal damage (Burgoyne et al., 2005). In this way, the rat eye presents an opportunity to understand the
288
specific cellular mechanisms leading to glaucomatous optic nerve damage.
Methods for measuring IOP in rats
The handheld Tono-Pen tonometer was the first instrument used successfully to measure IOP in rats (Moore et al., 1993, 1995). This instrument, designed for use in humans, works when held either horizontally or vertically. Based on the MacKay–Marg principle, the Tono-Pen tip consists an annulus that lies flush with the tip of a central post that is connected to a strain gauge fixed in the body of the instrument. Contacting the tip with the cornea causes the post to move relative to the annulus. Internal processors analyze the waveform of this movement and display pressure readings that result from acceptable waveforms. The instrument then calculates and displays an average of several acceptable readings along with the percent standard deviation, which is a statistical measure of the repeatability of these measurements, but not a true reflection of accuracy. Thus, a consistent error in the measurement technique can produce the wrong pressure reading, despite an excellent standard deviation.
In our initial evaluation, pressures measured by the Tono-Pen in cannulated eyes connected to a pressure transducer correlated well with the actual IOP (Moore et al., 1993) (Fig. 3a). We found that
individual valid readings were associated with contact of the instrument tip with the cornea firm enough to move the eye slightly posterior. Invalid readings were found to result from overly hard contact with the cornea (producing an inaccurately high reading) and from too light a contact, which is generally recognized by a single-digit reading (resulting from tear film contact only) and no posterior eye movement. Other inaccurate readings are those that occur when the tip breaks contact with the cornea (‘‘off’’ readings). Because the Tono-Pen cannot identify these readings as inaccurate, the instrument-generated ‘‘averages’’ will also be unreliable. Therefore, it is best to note individual valid readings and calculate the mean of these readings (Moore et al., 1993). This reliability has been well documented by good correlations between pressure readings in eyes with elevated IOP and nerve damage, as well as many cellular responses in the ONH and the retina (Jia et al., 2000b; Johnson et al., 2000, 2006, 2007; Schlamp et al., 2001; Ahmed et al., 2004; Fortune et al., 2004; Morrison et al., 2005; Pang et al., 2005a).
The Tono-Pen, however, possesses some disadvantages. Because it is designed for use with the human eye, which has a larger corneal curvature, the tip and the central post are relatively large for use in rats. This means that the instrument must be held exactly perpendicular to the cornea and centered perfectly on its apex to obtain acceptable readings. This reduced tolerance for even slight
Fig. 3. Calibration curves for Tono-Pen (a) and TonoLab (b). Note linear relationship between Tono-Pen readings and actual transducer pressure. TonoLab pressure readings are consistently below transducer pressures, with flattening of this relationship below transducer pressure of 20 mmHg.
